Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327014 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
A Phase 2 study of Hyperlipidemia, sponsored by Beijing Peking University WBL Biotech Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 13
- Study locations
NCT01327014 is a Phase 2 study of Hyperlipidemia that has completed, run by Beijing Peking University WBL Biotech Co.. The registered enrollment target is 116 participants, below the 405-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (71% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT01327014, a Phase 2 study of Hyperlipidemia, has completed, sponsored by Beijing Peking University WBL Biotech Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XueZhiKang (XZK), a botanic product with multiple components
Study Locations (13)
Texas
- Osvaldo Brusco, MD - Corpus Christi
- Clinical Trial Network - Houston
Shanghai Municipality
- Shanghai Ruijin Hospital - Shanghai
- Shanghai First People's Hospital - Shanghai
California
- Robert Karns, MD A Medical Corporation - Beverly Hills
Florida
- Jellinger and Lerman, MD - Hollywood
Kansas
- Department of Internal Medicine, University of Kansas Medical Center - Kansas City
Kentucky
- Harold E Bays, MD - Louisville
Ohio
- Eli M Roth, MD - Cincinnati
Pennsylvania
- Cardiovascular Medical Associates - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327014
The ClinicalTrials.gov registry entry for NCT01327014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 405-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (71% lower). The listed sponsor is Beijing Peking University WBL Biotech Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01327014 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Texas, Shanghai Municipality, California.
Frequently Asked Questions
What is clinical trial NCT01327014 about?
NCT01327014 is a clinical study titled "Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia". The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.
What is the current status of trial NCT01327014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2011-04. Estimated completion is 2012-12.
What conditions does trial NCT01327014 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT01327014?
The interventions under investigation include: Placebo (DRUG), XueZhiKang (XZK), a botanic product with multiple components (DRUG).
Who is sponsoring clinical trial NCT01327014?
This trial is sponsored by Beijing Peking University WBL Biotech Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01327014 being conducted?
This trial has 13 study locations across California, Florida, Kansas, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
The SCCS Polypill Pilot Trial
COMPLETED · Phase 2
-
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
COMPLETED · Phase 2
-
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
COMPLETED · Phase 2
-
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.